Skip to main content
SpringerLink
Log in

AXL and acquired resistance to EGFR inhibitors

  • News & Views
  • Published:

From Nature Genetics

View current issue Submit your manuscript

A combination of in vitro and in vivo models with validation in human tumors has identified AXL activation as a new mechanism of acquired resistance to EGFR inhibitors in non–small cell lung cancer. The identification of this mechanism, alongside the current development of specific AXL inhibitors, provides the rationale for further studies that may improve treatment for EGFR inhibitor–resistant patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Acquired resistance to EGFR-targeted TKIs caused by activation of the AXL kinase.

Katie Vicari

References

  1. Lynch, T.J. et al. N. Engl. J. Med. 350, 2129–2139 (2004).

    Article  CAS  Google Scholar 

  2. Paez, J.G. et al. Science 304, 1497–1500 (2004).

    Article  CAS  Google Scholar 

  3. Pao, W. et al. Proc. Natl. Acad. Sci. USA 101, 13306–13311 (2004).

    Article  CAS  Google Scholar 

  4. Sequist, L.V. et al. Sci. Transl. Med. 3, 75ra26 (2011).

    Article  Google Scholar 

  5. Oxnard, G.R. et al. Clin. Cancer Res. 17, 1616–1622 (2011).

    Article  CAS  Google Scholar 

  6. Zhang, Z. et al. Nat. Genet. 44, 852–860 (2012).

    Article  CAS  Google Scholar 

  7. Verma, A., Warner, S.L., Vankayalapati, H., Bearss, D.J. & Sharma, S. Mol. Cancer Ther. 10, 1763–1773 (2011).

    Article  CAS  Google Scholar 

  8. Linger, R.M., Keating, A.K., Earp, H.S. & Graham, D.K. Expert Opin. Ther. Targets 14, 1073–1090 (2010).

    Article  CAS  Google Scholar 

  9. Ye, X. et al. Oncogene 29, 5254–5264 (2010).

    Article  CAS  Google Scholar 

  10. Imai, K. & Takaoka, A. Nat. Rev. Cancer 6, 714–727 (2006).

    Article  CAS  Google Scholar 

  11. Jackman, D. et al. J. Clin. Oncol. 28, 357–360 (2010).

    Article  CAS  Google Scholar 

  12. Chaft, J.E. et al. Clin. Cancer Res. 17, 6298–6303 (2011).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sophie Postel-Vinay and Alan Ashworth are at The Breakthrough Breast Cancer Research Centre at The Institute of Cancer Research, London, UK.,

    Sophie Postel-Vinay & Alan Ashworth

  2. Département de Médecine–Institut National de la Santé et de la Recherche Médicale (INSERM) U981, Sophie Postel-Vinay is also at Institut Gustave Roussy, Villejuif, France.,

    Sophie Postel-Vinay

Authors
  1. Sophie Postel-Vinay
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alan Ashworth
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Sophie Postel-Vinay or Alan Ashworth.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Postel-Vinay, S., Ashworth, A. AXL and acquired resistance to EGFR inhibitors. Nat Genet 44, 835–836 (2012). https://doi.org/10.1038/ng.2362

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ng.2362

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation